drugset / Trial / NCT00843986

Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)

NCT00843986

Phase 3 Terminated 9 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and effectiveness of Conivaptan, a vasopressin antagonist, in the treatment of hyponatremic subjects having symptomatic acute decompensated heart failure (ADHF).

Timeline

Start
2009-04
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Conivaptan Small molecule 20 mg Intravenous

Indications